DarT Bioscience Inc

Daré Bioscience Inc. a clinical-stage biopharmaceutical company engages in the identifying developing and marketing products for women's health in the United States. It develops therapies in the areas of contraception reproductive health menopause fertility and sexual and vaginal health. The company's product includes XACIATO a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene a hormone-free monthly intravaginal contraceptive; Sildenafil Cream a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1 a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1 a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1 a proprietary hydrogel formulation of diclofenac a nonsteroidal anti-inflammatory drug for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214 an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1 an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan as well as DARE-PTB1 an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1 a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt